OBI Pharma, based in Taipei, has received a significant boost after the US Food and Drug Administration (FDA) granted Orphan Drug Designation to its experimental cancer therapy OBI-902, paving the way for the development of a treatment for cholangiocarcinoma, a rare and rapidly spreading bile duct cancer affecting fewer than 50,000 Americans. 

The classification is important because it offers benefits to drug researchers, like tax breaks for clinical studies, exemptions from certain fees, and seven years of exclusive rights to sell the drug, encouraging new treatments for diseases that affect small numbers of people. In the United States, a rare disease is defined as one that affects fewer than 200,000 persons. 

Cholangiocarcinoma is still one of the most fatal malignancies, with five-year survival rates ranging from 2% to 23%, depending on stage and subtype. There are no FDA-approved antibody-drug conjugates (ADCs) for this cancer; therefore, OBI-902 could be a first-in-class treatment option. 

ADCs are sophisticated cancer treatments that function similarly to targeted missiles: they employ an antibody to identify cancer cells and deliver a potent chemical straight to them. OBI-902 targets TROP2, a protein discovered in high quantities in a variety of malignancies, including breast, lung, ovarian, stomach, and bile duct. The therapy includes a topoisomerase I inhibitor, which inhibits cancer cells from replicating their DNA, eventually destroying them. OBI's technology uses glycan conjugation, a method that better attaches the medicine to the antibody, making it more stable and reducing unwanted side effects. 

OBI Pharma's patented GlycOBI® platform also improves the molecule's water-friendly qualities, allowing it to circulate more efficiently in the blood. Scientists think these qualities enhance the "bystander effect"—the ability of the medicine to kill surrounding cancer cells even if they lack TROP2 expression—while potentially overcoming treatment resistance. 

OBI Pharma's CEO, Heidi Wang, stated that the findings from early trials are favourable. Preclinical evidence suggests that OBI-902 has significant benefits over other TROP2 ADCs. "We are eager to explore this potential best-in-class TROP2 ADC in clinical settings," she expressed. 

In August 2025, OBI started a Phase I/II clinical trial in the United States and Taiwan to check how safe the drug is, how it moves through the body (pharmacokinetics), and how well it works in patients with advanced 

OBI owns the global commercial rights to OBI-902 except in China, where the antibody component is licensed from Biosion, Inc. The FDA had previously cleared the investigational new drug (IND) application in April 2025. 

If clinical results stay encouraging, OBI-902 could become an important addition to the limited therapy choices for individuals suffering from this rare and lethal malignancy.